Terminated PHASE2 INTERVENTIONAL 2-arm NCT03344172

Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer (17-134)

Randomized Phase II Trial of Pre-Operative Gemcitabine, Nab-Paclitaxel, and Hydroxychloroquine With or Without Avelumab (PGHA vs. PGH)

Sponsor: Nathan Bahary, MD

Conditions Pancreatic Cancer Resectable

Interventions Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab

Updated 9 times since 2017 Last updated: Apr 30, 2020 Started: Dec 13, 2017 Primary completion: Apr 30, 2019 Completion: Apr 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Suspected Serious Adverse Events related to treatment

Other terminated trials from Nathan Bahary, MD

Borderline Resectable Pancreatic Cancer · Phase PHASE2 · Mar 2017

More terminations from Nathan Bahary, MD

This PHASE2 trial investigates Pancreatic Cancer Resectable and is currently terminated or withdrawn. Nathan Bahary, MD leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2020 — Jan 2021 [monthly]

Terminated PHASE2

Status: Suspended → Terminated
Jun 2019 — Jun 2020 [monthly]

Suspended PHASE2

Status: Recruiting → Suspended

▶ Show 4 earlier versions

Jan 2019 — Jun 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Jan 2019 [monthly]

Recruiting PHASE2
Jan 2018 — Jun 2018 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2017 — Jan 2018 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nathan Bahary, MD
National Cancer Institute (NCI)
Pfizer

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States